Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Introduction to the topic: Off-label use of bevacizumab in the treatment of neovascular age-related macular degeneration].

× No keyword cloud information.

7 in total

1. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

Authors: Philip J Rosenfeld; Andrew A Moshfeghi; Carmen A Puliafito
Journal: Ophthalmic Surg Lasers Imaging Date: 2005 Jul-Aug

2. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis.

Authors: Christine R Gonzales
Journal: Retina Date: 2005 Oct-Nov Impact factor: 4.256

3. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Authors: Robert L Avery; Dante J Pieramici; Melvin D Rabena; Alessandro A Castellarin; Ma'an A Nasir; Matthew J Giust
Journal: Ophthalmology Date: 2006-02-03 Impact factor: 12.079

4. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor.

Authors: D R Senger; D T Connolly; L Van de Water; J Feder; H F Dvorak
Journal: Cancer Res Date: 1990-03-15 Impact factor: 12.701

5. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165.

Authors: Joon-Hwa Lee; Marella D Canny; Andrea De Erkenez; Dominik Krilleke; Yin-Shan Ng; David T Shima; Arthur Pardi; Fiona Jucker
Journal: Proc Natl Acad Sci U S A Date: 2005-12-15 Impact factor: 11.205

6. Pegaptanib for neovascular age-related macular degeneration.

Authors: Evangelos S Gragoudas; Anthony P Adamis; Emmett T Cunningham; Matthew Feinsod; David R Guyer
Journal: N Engl J Med Date: 2004-12-30 Impact factor: 91.245

7. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.

Authors: Susumu Ishida; Tomohiko Usui; Kenji Yamashiro; Yuichi Kaji; Shiro Amano; Yuichiro Ogura; Tetsuo Hida; Yoshihisa Oguchi; Jayakrishna Ambati; Joan W Miller; Evangelos S Gragoudas; Yin-Shan Ng; Patricia A D'Amore; David T Shima; Anthony P Adamis
Journal: J Exp Med Date: 2003-08-04 Impact factor: 14.307

7 in total

6 in total

1. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.

Authors: Ratimir Lazic; Nikica Gabric
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2006-11-18 Impact factor: 3.117

2. [Intraocular application of bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks].

Authors: A Lommatzsch; G Spital; M Trieschmann; D Pauleikhoff
Journal: Ophthalmologe Date: 2007-04 Impact factor: 1.059

Review 3. [Age-related macular degeneration: a socioeconomic time bomb in our aging society].

Authors: W F Schrader
Journal: Ophthalmologe Date: 2006-09 Impact factor: 1.059

4. [Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress].

Authors: D Kook; A Wolf; A S Neubauer; C Haritoglou; S G Priglinger; A Kampik; M W Ulbig
Journal: Ophthalmologe Date: 2008-02 Impact factor: 1.059

5. [Intraocular injections of bevacizumab in rare indications--two cases].

Authors: T Wecke; C Knop; W Schreiber; W Behrens-Baumann
Journal: Ophthalmologe Date: 2009-05 Impact factor: 1.059

6. Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration.

Authors: Mohammad Riazi-Esfahani; Hamid Ahmadieh; Hooshang Faghihi; Niloofar Piri; Ramin Taei; Reza Karkhaneh; Zahra Alami-Harandi; Alireza Lashay; Ahmad Mirshahi; Mehdi Nili-Ahmadabadi; Masoud Soheilian; Masoumeh Sanagou
Journal: J Ophthalmic Vis Res Date: 2008-04

6 in total